Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 2/20 | 0.32 |
| ▸ | RXRB | P28702 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RXRG | P48443 | 1/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6135773 | 0.84 | ESR1 (0.39) | MEN1KMT2AALDH1A1 | |
| SCHEMBL25193124 | 0.77 | GPR84 (0.34) | KDM4EGAAMAPTRXRARXRB | |
| SCHEMBL11377784 | 0.77 | NQO1 (0.36) | KDM4EGAAMAPTALDH1A1 | |
| SCHEMBL22411205 | 0.72 | NQO1 (0.33) | ALDH1A1 | |
| SCHEMBL5335957 | 0.70 | GSTP1 (0.42) | KDM4EGPR84 | |
| SCHEMBL9651812 | 0.69 | CA2 (0.41) | GAAMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL5010176 | 0.69 | NQO1 (0.39) | KDM4EGAAMAPTNPC1ALDH1A1 | |
| SCHEMBL26965728 | 0.69 | ESR1 (0.40) | NPC1GPR84ALDH1A1 | |
| SCHEMBL22142542 | 0.68 | GAA (0.39) | KDM4EGAAMAPTRXRARXRB | |
| SCHEMBL3420318 | 0.68 | ALDH1A1 (0.40) | KDM4EGAAMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12297311-B2 | Biaryl hydroxythiophene group IV transition metal polymerization with chain transfer capability | DOW GLOBAL TECHNOLOGIES LLC (US) | 2025-05-13 | — | — | US | disclosed |
| US-20250051495-A1 | SUPPORTED CATALYST SYSTEMS CONTAINING A SILOCON BRIDGED, ANTHRACENYL SUBSTITUTED BIS-BIPHENYL-PHENOXY ORGANOMETALLIC COMPOUND FOR MAKING POLYETHYLENE AND POLYETHYLENE COPOLYMER RESINS IN A GAS PHASE POLYMERIZATION REACTOR | DOW GLOBAL TECHNOLOGIES LLC (US) | 2025-02-13 | — | — | US | disclosed |
| US-20250034292-A1 | SUPPORTED CATALYST SYSTEMS CONTAINING A GERMANIUM BRIDGED, ANTHRACENYL SUBSTITUTED BIS-BIPHENYL-PHENOXY ORGANOMETALLIC COMPOUND FOR MAKING POLYETHYLENE AND POLYETHYLENE COPOLYMER RESINS IN A GAS PHASE POLYMERIZATION REACTOR | DOW GLOBAL TECHNOLOGIES LLC (US) | 2025-01-30 | — | — | US | disclosed |
| US-20250011478-A1 | SUPPORTED CATALYST SYSTEMS CONTAINING A CARBON BRIDGED, ANTHRACENYL SUBSTITUTED BIS-BIPHENYL-PHENOXY ORGANOMETALLIC COMPOUND FOR MAKING POLYETHYLENE AND POLYETHYLENE COPOLYMER RESINS IN A GAS PHASE POLYMERIZATION REACTOR | DOW GLOBAL TECHNOLOGIES LLC (US) | 2025-01-09 | — | — | US | disclosed |
| US-12122862-B2 | Biaryl hydroxythiophene group IV transition metal polymerization catalysts with chain transfer capability | DOW GLOBAL TECHNOLOGIES LLC (US) | 2024-10-22 | — | — | US | disclosed |
| EP-4437012-A1 | SUPPORTED CATALYST SYSTEMS CONTAINING A CARBON BRIDGED, ANTHRACENYL SUBSTITUTED BIS-BIPHENYL-PHENOXY ORGANOMETALLIC COMPOUND FOR MAKING POLYETHYLENE AND POLY ETHYLENE COPOLYMER RESINS IN A GAS PHASE POLYMERIZATION REACTOR | Dow Global Technologies LLC (US) | 2024-10-02 | — | — | EP | disclosed |
| EP-4437011-A1 | SUPPORTED CATALYST SYSTEMS CONTAINING A GERMANIUM BRIDGED, ANTHRACENYL SUBSTITUTED BIS-BIPHENYL-PHENOXY ORGANOMETALLIC COMPOUND FOR MAKING POLYETHYLENE AND POLYETHYLENE COPOLYMER RESINS IN A GAS PHASE POLYMERIZATION REACTOR | Dow Global Technologies LLC (US) | 2024-10-02 | — | — | EP | disclosed |
| EP-4437013-A1 | SUPPORTED CATALYST SYSTEMS CONTAINING A SILOCON BRIDGED, ANTHRACENYL SUBSTITUTED BIS-BIPHENYL-PHENOXY ORGANOMETALLIC COMPOUND FOR MAKING POLYETHYLENE AND POLYETHYLENE COPOLYMER RESINS IN A GAS PHASE POLYMERIZATION REACTOR | Dow Global Technologies LLC (US) | 2024-10-02 | — | — | EP | disclosed |
| CN-118302456-A | Supported catalyst system containing germanium bridged, anthracenyl substituted bis-biphenyl-phenoxy organometallic compounds for preparing polyethylene and polyethylene copolymer resins in a gas phase polymerization reactor | 陶氏环球技术有限责任公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-118302457-A | Supported catalyst system containing carbon-bridged, anthracenyl-substituted bis-biphenyl-phenoxy organometallic compounds for preparing polyethylene and polyethylene copolymer resins in a gas phase polymerization reactor | 陶氏环球技术有限责任公司 | 2024-07-05 | — | — | CN | disclosed |
| WO-2023096865-A1 | SUPPORTED CATALYST SYSTEMS CONTAINING A SILOCON BRIDGED, ANTHRACENYL SUBSTITUTED BIS-BIPHENYL-PHENOXY ORGANOMETALLIC COMPOUND FOR MAKING POLYETHYLENE AND POLYETHYLENE COPOLYMER RESINS IN A GAS PHASE POLYMERIZATION REACTOR | DOW GLOBAL TECHNOLOGIES LLC (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023096868-A1 | SUPPORTED CATALYST SYSTEMS CONTAINING A GERMANIUM BRIDGED, ANTHRACENYL SUBSTITUTED BIS-BIPHENYL-PHENOXY ORGANOMETALLIC COMPOUND FOR MAKING POLYETHYLENE AND POLYETHYLENE COPOLYMER RESINS IN A GAS PHASE POLYMERIZATION REACTOR | DOW GLOBAL TECHNOLOGIES LLC (US) | 2023-06-01 | — | — | WO | disclosed |
| US-20220169756-A1 | BIARYL HYDROXYTHIOPHENE GROUP IV TRANSITION METAL POLYMERIZATION WITH CHAIN TRANSFER CAPABILITY | DOW GLOBAL TECHNOLOGIES LLC (US) | 2022-06-02 | — | — | US | disclosed |
| US-20220025085-A1 | BIARYL HYDROXYTHIOPHENE GROUP IV TRANSITION METAL POLYMERIZATION CATALYSTS WITH CHAIN TRANSFER CAPABILITY | DOW GLOBAL TECHNOLOGIES LLC (US) | 2022-01-27 | — | — | US | disclosed |
| EP-3935091-A1 | BIARYL HYDROXYTHIOPHENE GROUP IV TRANSITION METAL POLYMERIZATION WITH CHAIN TRANSFER CAPABILITY | Dow Global Technologies LLC (US) | 2022-01-12 | — | — | EP | disclosed |
| CN-113748138-A | Biaryl hydroxythiophene group IV transition metal polymerization with chain transfer capability | 陶氏环球技术有限责任公司 | 2021-12-03 | — | — | CN | disclosed |
| EP-3898724-A1 | BIARYL HYDROXYTHIOPHENE GROUP IV TRANSITION METAL POLYMERIZATION CATALYSTS WITH CHAIN TRANSFER CAPABILITY | Dow Global Technologies LLC (US) | 2021-10-27 | — | — | EP | disclosed |
| CN-113348186-A | Biaryl hydroxy thiophene IV group transition metal polymerization catalyst with chain transfer capability | 陶氏环球技术有限责任公司 | 2021-09-03 | — | — | CN | disclosed |
| WO-2020185494-A1 | BIARYL HYDROXYTHIOPHENE GROUP IV TRANSITION METAL POLYMERIZATION WITH CHAIN TRANSFER CAPABILITY | DOW GLOBAL TECHNOLOGIES LLC (US) | 2020-09-17 | — | — | WO | disclosed |
| WO-2020132244-A1 | BIARYL HYDROXYTHIOPHENE GROUP IV TRANSITION METAL POLYMERIZATION CATALYSTS WITH CHAIN TRANSFER CAPABILITY | DOW GLOBAL TECHNOLOGIES LLC (US) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220025085-A1 | BIARYL HYDROXYTHIOPHENE GROUP IV TRANSITION METAL POLYMERIZATION CATALYSTS WITH CHAIN TRANSFER CAPABILITY | TRMT1, GFPT1, BCAT1 | KDM4E 3184/4885GAA 2661/4885MAPT 430/4885 |
| US-12122862-B2 | Biaryl hydroxythiophene group IV transition metal polymerization catalysts with chain transfer capability | TRMT1, GFPT1, BCAT1 | KDM4E 3184/4885GAA 2661/4885MAPT 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.